Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A first-in-human phase 1 study of KB 9558 in multiple myeloma

Trial Profile

A first-in-human phase 1 study of KB 9558 in multiple myeloma

Status: Planning
Phase of Trial: Phase I

Latest Information Update: 04 Sep 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs KB 9558 (Primary)
  • Indications Multiple myeloma
  • Focus Adverse reactions

Most Recent Events

  • 04 Sep 2024 According to a Kronos Bio media release, the company will present oral presentation at the International Myeloma Society (IMS) 21st Annual Meeting, taking place September 25 - 28, 2024 in Rio de Janeiro, Brazil.
  • 21 Mar 2024 According to a Kronos Bio media release, IND-enabling studies for KB-9558 expected to complete in 2024 with first-in-human study anticipated to commence and expect to dose first patients in the first half of 2025.
  • 12 Mar 2024 New trial record

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top